SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Momenta Pharmaceuticals Inc. -- Ignore unavailable to you. Want to Upgrade?


To: Biomaven who wrote (2690)12/29/2010 4:43:19 PM
From: IRWIN JAMES FRANKEL  Respond to of 3027
 
That is the only one I recall.

I would add that it is characteristically different to tell an agency to make a decision than to tell it what decision to make or second-guess a decision made.

The latter is a higher hurdle.

One more thing. Much is being made about internal disagreement within the FDA as if that is somehow dispositive. I would suggest that many if not most difficult decisions will have internal agency dissenters. Ultimately someone has to make decisions and I consider it likely that the decisions will be better if made in the face of serious debate. Substituting a courts view for the agency will not happen often.

ij



To: Biomaven who wrote (2690)12/29/2010 5:20:22 PM
From: Arthur Radley  Respond to of 3027
 
Good memory.........was in 2005.
drugs.com



To: Biomaven who wrote (2690)12/31/2010 1:18:59 PM
From: semi_infinite   Read Replies (1) | Respond to of 3027
 
So for practical purposes Amphastar is doing their 70 yard Hail Mary play and it takes another 3 years to change the scoreboard if the pass is completed. Teva seems like they are close to doing a similar play with their public complaints aired in the WSJ. I shall continue to take advantage of fat fear and greed premiums. So far collected 25K or so while long 5K shares so my cost basis is down around $10/shr now. Around the same level that people anticipate in the event of tL clearance.